{"id":"W4417173712","doi":"10.1212/wnl.0000000000214441","title":"Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Neurology","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"National Institute on Aging; Canadian Institutes of Health Research; National Institutes of Health; Genentech; IXICO; H. Lundbeck A/S; Servier; Eisai; National Research Foundation of Korea; Eli Lilly and Company; Bristol-Myers Squibb; Korea Disease Control and Prevention Agency; Pfizer; Novartis Pharmaceuticals Corporation; U.S. Department of Defense; Meso Scale Diagnostics; Ministry of Science and ICT, South Korea; BioClinica; National Research Foundation; Biogen; Korea Health Industry Development Institute","keywords":"Clinical trial; Clinical endpoint; Alzheimer's disease; Disease; Endpoint Determination; Degenerative disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.155461,0.001506328,0.003937112,0.001080929,0.0009589868,0.0025422,0.001607078,0.002723357,0.003132326],"category_scores_gemma":[0.1291232,0.0005576921,0.005196179,0.001647342,0.001464925,0.00246778,0.001623687,0.002419768,0.0005751131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001048941,"about_ca_system_score_gemma":0.002497261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000253271,"about_ca_topic_score_gemma":0.0003255553,"domain_scores_codex":[0.8403948,0.1350572,0.01198757,0.00480657,0.006777723,0.0009761423],"domain_scores_gemma":[0.8526008,0.09976988,0.02959674,0.007586522,0.008083385,0.002362684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6299962,0.003353094,0.1863123,0.01058686,0.04945026,0.000348453,0.0006384565,0.008165384,0.003125794,0.004271133,0.00715195,0.09660015],"study_design_scores_gemma":[0.2597054,0.2423258,0.3308938,0.003155875,0.0532047,0.0009335965,0.0004823515,0.03989163,0.006969161,0.01996504,0.04209704,0.0003756806],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7722944,0.07315941,0.06467006,0.005528721,0.00309904,0.05360793,0.008784571,0.0005089237,0.01834686],"genre_scores_gemma":[0.9330488,0.002982871,0.01807775,0.001491947,0.0007048006,0.04074559,0.001939777,0.00005485376,0.0009536089],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.155461,"threshold_uncertainty_score":0.822166,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3383309256269542,"score_gpt":0.5679183984959794,"score_spread":0.2295874728690251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}